

Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology.

Table S1. Patients with primary metastatic bladder cancer diagnosed between 2008-2016 in Norway: Patient characteristics for patients still alive at end of follow-up (31st of December 2019)

	Survivors
Patients, n (%)	11(4%)
Age (years, IQR)	70(55,73)
Sex (%female)	6(55)
Year of diagnosis	
2008-2010	5(46)
2011-2013	3(27)
2014-2016	3(27)
Metastases	
Lymph nodes, non-regional (LN)	6(55)
Visceral	5(45)
Primary treatment, n (%)	
Systemic chemotherapy	5(45)
Major local	2(18)
Multimodal	1(9)
Untreated	3(27)

Table S2. Patients with primary metastatic bladder cancer diagnosed between 2008-2016 in Norway : Treatment sequences within 150 days after diagnosis of bladder cancer for patients treated with a combination of initial local tumour treatment and systemic anti-cancer treatment by initial treatment (cystectomy or chemotherapy).

Initial treatment	Cystectomy	Chemotherapy
Patients, n=21 (%)	10 (42)	11(46)
Subsequent treatment combinations		
TURB*	0	1(9)
Cystectomy	0	2(18)
Pelvic radiotherapy of bladder	1(10)	8(73)
Chemotherapy	9(90)	0

* Transurethral resection of bladder tumour